The P/E of -11.08 reflects trailing losses, leaving earnings-based valuation unusable and forcing reliance on sales and book multiples. A P/B of 4.16 against equity of roughly $164M implies the market values the commercial franchise well above its accounting base, which is typical for growth-stage biotech but offers little margin of safety. The valuation therefore rests on the durability of revenue growth rather than on any demonstrated earnings power.

Gross margin stabilized near 95 to 96%, confirming a high-margin product structure, but the gap between operating and net margin shows that financing and other costs remain material. The 2026Q2 net margin of -13.8% against a 2026Q3 figure near breakeven suggests the trajectory is improving but not yet structurally sound. Margin durability depends on whether gross-to-net pressure stays contained as formulary competition intensifies.

Interest coverage was negative in several recent quarters, indicating operating income has not reliably covered financing costs, and the D/EBITDA ratio of 63.7 in the latest period reflects a thin earnings base rather than a debt load that is easily serviced. Refinancing and covenant risk warrant closer scrutiny given the rising debt balance relative to equity. The leverage trend is less comfortable than the headline current ratio implies.

A high current ratio is partly driven by receivables and inventory rather than cash, so the quick ratio of 3.26 is the more relevant measure, though it still depends on collection timing. Given quarterly cash burn in several periods, the company would likely depend on financing access to sustain operations through a prolonged downturn. The data do not reveal the terms or availability of any facilities, so that dependence remains an inference.